The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
The emerging role of the Nrf2–Keap1 signaling pathway in cancer
Open accessAbstract
The Nrf2 (nuclear factor erythroid 2 [NF-E2]-related factor 2 [Nrf2])–Keap1 (Kelch-like erythroid cell-derived protein with CNC homology [ECH]-associated protein 1) signaling pathway is one of the most important cell defense and survival pathways. Nrf2 can protect cells and tissues from a variety of toxicants and carcinogens by increasing the expression of a number of cytoprotective genes. As a result, several Nrf2 activators are currently being tested as chemopreventive compounds in clinical trials. Just as Nrf2 protects normal cells, studies have shown that Nrf2 may also protect cancer cells from chemotherapeutic agents and facilitate cancer progression. Nrf2 is aberrantly accumulated in many types of cancer, and its expression is associated with a poor prognosis in patients. In addition, Nrf2 expression is induced during the course of drug resistance. Collectively, these studies suggest that Nrf2 contributes to both intrinsic and acquired chemoresistance. This discovery has opened up a broad spectrum of research geared toward a better understanding of the role of Nrf2 in cancer. This review provides an overview of (1) the Nrf2–Keap1 signaling pathway, (2) the dual role of Nrf2 in cancer, (3) the molecular basis of Nrf2 activation in cancer cells, and (4) the challenges in the development of Nrf2-based drugs for chemoprevention and chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J. D., & Yamamoto, M. (1999) · Genes & Development · doi:10.1101/gad.13.1.76 · Cited by 3,634 · cited 2×
“The Kelch/ DGR domain is critical for maintaining the interaction between Nrf2 and Keap1 by interacting with the Neh2 domain of Nrf2 (Itoh et al. 1999; McMahon et al. 2004).”
BackgroundCell Survival Responses to Environmental Stresses Via the Keap1-Nrf2-ARE Pathway
Kensler, T. W., Wakabayashi, N., & Biswal, S. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141046 · Cited by 3,630
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Komatsu, M., Kurokawa, H., Waguri, S., Taguchi, K., Kobayashi, A., Ichimura, Y., Sou, Y.-S., Ueno, I., Sakamoto, A., Tong, K. I., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2021 · Cited by 2,288
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277
Kobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., & Yamamoto, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7130-7139.2004 · Cited by 2,224
Dinkova-Kostova, A. T., Holtzclaw, W. D., Cole, R. N., Itoh, K., Wakabayashi, N., Katoh, Y., Yamamoto, M., & Talalay, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398899 · Cited by 1,947
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114287 · Cited by 1,733
Nrf2–Keap1 defines a physiologically important stress response mechanism
Motohashi, H., & Yamamoto, M. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.09.003 · Cited by 1,725 · cited 1×
“…to protect against neurodegenerative diseases, aging, diabetes, photo-oxidative stress, cardiovascular dis- ease, inflammation, pulmonary fibrosis, acute pulmonary injury, and cancer (for review, see Motohashi and Yamamoto 2004; Jeong et al. 2006; Zhang 2006; Kensler et al. 2007; Lau et al. 2008).”
BackgroundMoi, P., Chan, K., Asunis, I., Cao, A., & Kan, Y. W. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.9926 · Cited by 1,607
Zhang, D. D., & Hannink, M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.22.8137-8151.2003 · Cited by 1,480 · cited 1×
“The human Keap1 protein contains 27 cysteine residues that can be oxidized to sulfenic acid, form disulfides, or be covalently adducted by electrophiles (Dinkova-Kostova et al. 2002; Zhang and Hannink 2003; McMahon et al. 2010).”
BackgroundSelf-citationJain, A., Lamark, T., Sjøttem, E., Bowitz Larsen, K., Atesoh Awuh, J., Øvervatn, A., McMahon, M., Hayes, J. D., & Johansen, T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.118976 · Cited by 1,472
Rushmore, T. H., Morton, M. R., & Pickett, C. B. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99004-6 · Cited by 1,464
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M., & Motohashi, H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.016 · Cited by 1,395 · cited 2×
“Recently, Mitsuishi et al. (2012) demonstrated that Nrf2 is indeed important for the ability of A549 lung cancer cells to proliferate.”
BackgroundKeap1 Is a Redox-Regulated Substrate Adaptor Protein for a Cul3-Dependent Ubiquitin Ligase Complex
Zhang, D. D., Lo, S.-C., Cross, J. V., Templeton, D. J., & Hannink, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.24.10941-10953.2004 · Cited by 1,254
Self-citationIntegrated molecular analysis of clear-cell renal cell carcinoma
Sato, Y., Yoshizato, T., Shiraishi, Y., Maekawa, S., Okuno, Y., Kamura, T., Shimamura, T., Sato-Otsubo, A., Nagae, G., Suzuki, H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2699 · Cited by 1,221
Ishimoto, T., Nagano, O., Yae, T., Tamada, M., Motohara, T., Oshima, H., Oshima, M., Ikeda, T., Asaba, R., Yagi, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.038 · Cited by 1,192
Ramos-Gomez, M., Kwak, M.-K., Dolan, P. M., Itoh, K., Yamamoto, M., Talalay, P., & Kensler, T. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051618798 · Cited by 1,102
Mechanistic Studies of the Nrf2-Keap1 Signaling Pathway
Zhang, D. D. (2006) · Drug Metabolism Reviews · doi:10.1080/03602530600971974 · Cited by 1,086
Self-citationDysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer
Singh, A., Misra, V., Thimmulappa, R. K., Lee, H., Ames, S., Hoque, M. O., Herman, J. G., Baylin, S. B., Sidransky, D., Gabrielson, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030420 · Cited by 1,060
BALOGUN, E., HOQUE, M., GONG, P., KILLEEN, E., GREEN, C. J., FORESTI, R., ALAM, J., & MOTTERLINI, R. (2003) · Biochemical Journal · doi:10.1042/bj20021619 · Cited by 1,036
The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation
Bryan, H. K., Olayanju, A., Goldring, C. E., & Park, B. K. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.016 · Cited by 1,024
Cullinan, S. B., Gordan, J. D., Jin, J., Harper, J. W., & Diehl, J. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8477-8486.2004 · Cited by 986
Lau, A., Wang, X.-J., Zhao, F., Villeneuve, N. F., Wu, T., Jiang, T., Sun, Z., White, E., & Zhang, D. D. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00248-10 · Cited by 849
Self-citationNrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2
Wang, X.-J., Sun, Z., Villeneuve, N. F., Zhang, S., Zhao, F., Li, Y., Chen, W., Yi, X., Zheng, W., Wondrak, G. T., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn095 · Cited by 839
Self-citationFahey, J. W., Haristoy, X., Dolan, P. M., Kensler, T. W., Scholtus, I., Stephenson, K. K., Talalay, P., & Lozniewski, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.112203099 · Cited by 795
Small Molecule Modulators of Keap1‐ Nrf2‐ ARE Pathway as Potential Preventive and Therapeutic Agents
Magesh, S., Chen, Y., & Hu, L. (2012) · Medicinal Research Reviews · doi:10.1002/med.21257 · Cited by 760 · cited 1×
“Several other small molecules have been found to suppress the Nrf2 pathway, including ascorbic acid, luteolin, ochratoxin A, trigonelline, and all-trans retinoic acid (ATRA) (for review, see Magesh et al. 2012).”
BackgroundTong, K. I., Katoh, Y., Kusunoki, H., Itoh, K., Tanaka, T., & Yamamoto, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.8.2887-2900.2006 · Cited by 759
Rada, P., Rojo, A. I., Chowdhry, S., McMahon, M., Hayes, J. D., & Cuadrado, A. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01204-10 · Cited by 759 · cited 2×
“Phosphorylation of the DSGIS motif by GSK-3 increases the ability of β-TrCP to ubiquitinate Nrf2 and promote its rapid turnover (McMahon et al. 2004; Rada et al. 2011; Chowdhry et al. 2013).”
BackgroundFurukawa, M., & Xiong, Y. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.1.162-171.2005 · Cited by 746
Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer
Padmanabhan, B., Tong, K. I., Ohta, T., Nakamura, Y., Scharlock, M., Ohtsuji, M., Kang, M.-I., Kobayashi, A., Yokoyama, S., & Yamamoto, M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.013 · Cited by 735 · cited 2×
“Gain-of-function mutations in NRF2 and loss-of-function mutations in KEAP1 and CUL3 have been identified in several human cancers (Padmanabhan et al. 2006; Singh et al. 2006; Nioi and Nguyen 2007; Ohta et al. 2008; Shibata et al. 2008a; Li et al. 2011; Ooi et al. 2013; Sato et al. 2013).”
BackgroundShibata, T., Ohta, T., Tong, K. I., Kokubu, A., Odogawa, R., Tsuta, K., Asamura, H., Yamamoto, M., & Hirohashi, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806268105 · Cited by 728
Functional antioxidant responsive elements
Wasserman, W. W., & Fahl, W. E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5361 · Cited by 705
Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism
Ren, D., Villeneuve, N. F., Jiang, T., Wu, T., Lau, A., Toppin, H. A., & Zhang, D. D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014275108 · Cited by 673
Self-citationRole of NRF2 in Protection Against Hyperoxic Lung Injury in Mice
Cho, H.-Y., Jedlicka, A. E., Reddy, S. P. M., Kensler, T. W., Yamamoto, M., Zhang, L.-Y., & Kleeberger, S. R. (2002) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.26.2.4501 · Cited by 659
Chowdhry, S., Zhang, Y., McMahon, M., Sutherland, C., Cuadrado, A., & Hayes, J. D. (2013) · Oncogene · doi:10.1038/onc.2012.388 · Cited by 657
LAU, A., VILLENEUVE, N., SUN, Z., WONG, P., & ZHANG, D. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.09.003 · Cited by 645
Self-citationDirect Interaction between Nrf2 and p21Cip1/WAF1 Upregulates the Nrf2-Mediated Antioxidant Response
Chen, W., Sun, Z., Wang, X.-J., Jiang, T., Huang, Z., Fang, D., & Zhang, D. D. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.04.029 · Cited by 638
Self-citationLoss of Keap1 Function Activates Nrf2 and Provides Advantages for Lung Cancer Cell Growth
Ohta, T., Iijima, K., Miyamoto, M., Nakahara, I., Tanaka, H., Ohtsuji, M., Suzuki, T., Kobayashi, A., Yokota, J., Sakiyama, T., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5003 · Cited by 629
Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling
Lo, S., Li, X., Henzl, M. T., Beamer, L. J., & Hannink, M. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601243 · Cited by 604 · cited 1×
“The BTB domain binds Cul3 and is required for Keap1 dimerization (Zipper and Mulcahy 2002; Lo et al. 2006).”
BackgroundWhen NRF2 Talks, Who's Listening?
Wakabayashi, N., Slocum, S. L., Skoko, J. J., Shin, S., & Kensler, T. W. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3216 · Cited by 595
Adam, J., Hatipoglu, E., O'Flaherty, L., Ternette, N., Sahgal, N., Lockstone, H., Baban, D., Nye, E., Stamp, G. W., Wolhuter, K., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.006 · Cited by 585
Cancer Chemoprevention Mechanisms Mediated Through the Keap1–Nrf2 Pathway
Hayes, J. D., McMahon, M., Chowdhry, S., & Dinkova-Kostova, A. T. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3221 · Cited by 539
Katoh, Y., Itoh, K., Yoshida, E., Miyagishi, M., Fukamizu, A., & Yamamoto, M. (2001) · Genes to Cells · doi:10.1046/j.1365-2443.2001.00469.x · Cited by 520
McMahon, M., Thomas, N., Itoh, K., Yamamoto, M., & Hayes, J. D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601119200 · Cited by 485
Nrf2: friend or foe for chemoprevention?
Kensler, T. W., & Wakabayashi, N. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp231 · Cited by 484
Keap1 degradation by autophagy for the maintenance of redox homeostasis
Taguchi, K., Fujikawa, N., Komatsu, M., Ishii, T., Unno, M., Akaike, T., Motohashi, H., & Yamamoto, M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121572109 · Cited by 482
Two-site substrate recognition model for the Keap1-Nrf2 system: A hinge and latch mechanism
Tong, K. I., Kobayashi, A., Katsuoka, F., & Yamamoto, M. (2006) · Biological Chemistry · doi:10.1515/bc.2006.164 · Cited by 473
Shibata, T., Kokubu, A., Gotoh, M., Ojima, H., Ohta, T., Yamamoto, M., & Hirohashi, S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.082 · Cited by 468
McMahon, M., Lamont, D. J., Beattie, K. A., & Hayes, J. D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007387107 · Cited by 443
Tong, K. I., Padmanabhan, B., Kobayashi, A., Shang, C., Hirotsu, Y., Yokoyama, S., & Yamamoto, M. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00753-07 · Cited by 442
Nrf2–MafG heterodimers contribute globally to antioxidant and metabolic networks
Hirotsu, Y., Katsuoka, F., Funayama, R., Nagashima, T., Nishida, Y., Nakayama, K., Douglas Engel, J., & Yamamoto, M. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks827 · Cited by 431
Solis, L. M., Behrens, C., Dong, W., Suraokar, M., Ozburn, N. C., Moran, C. A., Corvalan, A. H., Biswal, S., Swisher, S. G., Bekele, B. N., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3352 · Cited by 428
Nrf2 Enhances Cell Proliferation and Resistance to Anticancer Drugs in Human Lung Cancer
Homma, S., Ishii, Y., Morishima, Y., Yamadori, T., Matsuno, Y., Haraguchi, N., Kikuchi, N., Satoh, H., Sakamoto, T., Hizawa, N., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2822 · Cited by 418
McMahon, M., Thomas, N., Itoh, K., Yamamoto, M., & Hayes, J. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403061200 · Cited by 404
Ooi, A., Wong, J.-C., Petillo, D., Roossien, D., Perrier-Trudova, V., Whitten, D., Min, B. W. H., Tan, M.-H., Zhang, Z., Yang, X. J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.024 · Cited by 401 · cited 3×
“Fumarate, a Kreb cycle metabolite, was recently shown to form adducts with Keap1 and activate the Nrf2 signaling pathway in the hereditary form of type 2 papillary renal cell cancer (Ooi et al. 2011).”
BackgroundA role for mitochondrial enzymes in inherited neoplasia and beyond
Eng, C., Kiuru, M., Fernandez, M. J., & Aaltonen, L. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1013 · Cited by 392
The Keap1–Nrf2 system in cancers: stress response and anabolic metabolism
Mitsuishi, Y., Motohashi, H., & Yamamoto, M. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00200 · Cited by 392
Wang, H., Liu, K., Geng, M., Gao, P., Wu, X., Hai, Y., Li, Y., Li, Y., Luo, L., Hayes, J. D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3386 · Cited by 382
The Carboxy-Terminal Neh3 Domain of Nrf2 Is Required for Transcriptional Activation
Nioi, P., Nguyen, T., Sherratt, P. J., & Pickett, C. B. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.24.10895-10906.2005 · Cited by 381
Xu, C., Huang, M.-T., Shen, G., Yuan, X., Lin, W., Khor, T. O., Conney, A. H., & Kong, A.-N. T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0300 · Cited by 380
Transcriptional Regulation of the Antioxidant Response Element
Nguyen, T., Huang, H. C., & Pickett, C. B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000361200 · Cited by 378
Zhang, P., Singh, A., Yegnasubramanian, S., Esopi, D., Kombairaju, P., Bodas, M., Wu, H., Bova, S. G., & Biswal, S. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0589 · Cited by 374
Iida, K., Itoh, K., Kumagai, Y., Oyasu, R., Hattori, K., Kawai, K., Shimazui, T., Akaza, H., & Yamamoto, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1906 · Cited by 370
Singh, A., Boldin-Adamsky, S., Thimmulappa, R. K., Rath, S. K., Ashush, H., Coulter, J., Blackford, A., Goodman, S. N., Bunz, F., Watson, W. H., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1401 · Cited by 367
Nrf2: A Potential Molecular Target for Cancer Chemoprevention by Natural Compounds
Jeong, W.-S., Jun, M., & Kong, A.-N. T. (2006) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.8.99 · Cited by 367
The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm
Zipper, L. M., & Mulcahy, R. T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206530200 · Cited by 366 · cited 1×
“The BTB domain binds Cul3 and is required for Keap1 dimerization (Zipper and Mulcahy 2002; Lo et al. 2006).”
BackgroundMotohashi, H., Katsuoka, F., Engel, J. D., & Yamamoto, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0305902101 · Cited by 361
Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin
Kim, Y. R., Oh, J. E., Kim, M. S., Kang, M. R., Park, S. W., Han, J. Y., Eom, H. S., Yoo, N. J., & Lee, S. H. (2010) · The Journal of Pathology · doi:10.1002/path.2653 · Cited by 358
Sangokoya, C., Telen, M. J., & Chi, J.-T. (2010) · Blood · doi:10.1182/blood-2009-04-214817 · Cited by 357
Chung, F.-L. (2000) · Carcinogenesis · doi:10.1093/carcin/21.12.2287 · Cited by 350
p53 Suppresses the Nrf2-dependent Transcription of Antioxidant Response Genes
Faraonio, R., Vergara, P., Di Marzo, D., Pierantoni, M. G., Napolitano, M., Russo, T., & Cimino, F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605707200 · Cited by 349
Marzec, J. M., Christie, J. D., Reddy, S. P., Jedlicka, A. E., Vuong, H., Lanken, P. N., Aplenc, R., Yamamoto, T., Yamamoto, M., Cho, H.-Y., et al. (2007) · The FASEB Journal · doi:10.1096/fj.06-7759com · Cited by 340
Molecular basis for the contribution of the antioxidant responsive element to cancer chemoprevention
Hayes, J. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00695-4 · Cited by 323
Kensler, T. W., Chen, J.-G., Egner, P. A., Fahey, J. W., Jacobson, L. P., Stephenson, K. K., Ye, L., Coady, J. L., Wang, J.-B., Wu, Y., et al. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0368 · Cited by 317
Wang, X. J., Hayes, J. D., Henderson, C. J., & Wolf, C. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709483104 · Cited by 309
Wang, J.-S., Shen, X., He, X., Zhu, Y.-R., Zhang, B.-C., Wang, J.-B., Qian, G.-S., Kuang, S.-Y., Zarba, A., Egner, P. A., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.4.347 · Cited by 307
Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer
Khor, T. O., Huang, M.-T., Prawan, A., Liu, Y., Hao, X., Yu, S., Cheung, W. K. L., Chan, J. Y., Reddy, B. S., Yang, C. S., et al. (2008) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0028 · Cited by 306
miR-200a Regulates Nrf2 Activation by Targeting Keap1 mRNA in Breast Cancer Cells
Eades, G., Yang, M., Yao, Y., Zhang, Y., & Zhou, Q. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.275495 · Cited by 305
Fumarate Is Cardioprotective via Activation of the Nrf2 Antioxidant Pathway
Ashrafian, H., Czibik, G., Bellahcene, M., Aksentijević, D., Smith, A. C., Mitchell, S. J., Dodd, M. S., Kirwan, J., Byrne, J. J., Ludwig, C., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.01.017 · Cited by 302
High Levels of Nrf2 Determine Chemoresistance in Type II Endometrial Cancer
Jiang, T., Chen, N., Zhao, F., Wang, X.-J., Kong, B., Zheng, W., & Zhang, D. D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0713 · Cited by 286 · cited 6×
“In vivo xenografts derived from Nrf2 silenced lung cancer cells were more susceptible to platin-based chemotherapeutics compared with xenografts with control cells (Singh et al. 2008; Jiang et al. 2010).”
BackgroundInfluentialMiR-28 regulates Nrf2 expression through a Keap1-independent mechanism
Yang, M., Yao, Y., Eades, G., Zhang, Y., & Zhou, Q. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1604-1 · Cited by 280
Yates, M. S., Tran, Q. T., Dolan, P. M., Osburn, W. O., Shin, S., McCulloch, C. C., Silkworth, J. B., Taguchi, K., Yamamoto, M., Williams, C. R., et al. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp100 · Cited by 269
Copple, I. M., Lister, A., Obeng, A. D., Kitteringham, N. R., Jenkins, R. E., Layfield, R., Foster, B. J., Goldring, C. E., & Park, B. K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.096545 · Cited by 260
Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues
Wang, R., An, J., Ji, F., Jiao, H., Sun, H., & Zhou, D. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.06.004 · Cited by 259
Hast, B. E., Goldfarb, D., Mulvaney, K. M., Hast, M. A., Siesser, P. F., Yan, F., Hayes, D. N., & Major, M. B. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4400 · Cited by 259
Satoh, H., Moriguchi, T., Takai, J., Ebina, M., & Yamamoto, M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4499 · Cited by 251
Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy
Lister, A., Nedjadi, T., Kitteringham, N. R., Campbell, F., Costello, E., Lloyd, B., Copple, I. M., Williams, S., Owen, A., Neoptolemos, J. P., et al. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-37 · Cited by 242
Kensler, T. W., Egner, P. A., Dolan, P. M., Groopman, J. D., & Roebuck, B. D. (1987) · PubMed · Cited by 240
Conaway, C. C., Wang, C.-X., Pittman, B., Yang, Y.-M., Schwartz, J. E., Tian, D., McIntee, E. J., Hecht, S. S., & Chung, F.-L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0237 · Cited by 240
Ogura, T., Tong, K. I., Mio, K., Maruyama, Y., Kurokawa, H., Sato, C., & Yamamoto, M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914036107 · Cited by 229
Arsenic Inhibits Autophagic Flux, Activating the Nrf2-Keap1 Pathway in a p62-Dependent Manner
Lau, A., Zheng, Y., Tao, S., Wang, H., Whitman, S. A., White, E., & Zhang, D. D. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01748-12 · Cited by 229
Self-citationSeow, A. (2002) · Carcinogenesis · doi:10.1093/carcin/23.12.2055 · Cited by 227
A strategy for cancer prevention: Stimulation of the Nrf2-ARE signaling pathway
Zhang, Y., & Gordon, G. B. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.885.3.7 · Cited by 226
Shibata, T., Kokubu, A., Saito, S., Narisawa-Saito, M., Sasaki, H., Aoyagi, K., Yoshimatsu, Y., Tachimori, Y., Kushima, R., Kiyono, T., et al. (2011) · Neoplasia · doi:10.1593/neo.11750 · Cited by 224
A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity
Nioi, P., & Nguyen, T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.051 · Cited by 212
Gain of Nrf2 Function in Non-Small-Cell Lung Cancer Cells Confers Radioresistance
Singh, A., Bodas, M., Wakabayashi, N., Bunz, F., & Biswal, S. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3219 · Cited by 208
Accumulation of p62/SQSTM 1 is associated with poor prognosis in patients with lung adenocarcinoma
Inoue, D., Suzuki, T., Mitsuishi, Y., Miki, Y., Suzuki, S., Sugawara, S., Watanabe, M., Sakurada, A., Endo, C., Uruno, A., et al. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02216.x · Cited by 204
Ramos-Gomez, M. (2003) · Carcinogenesis · doi:10.1093/carcin/24.3.461 · Cited by 200
Osburn, W. O., Karim, B., Dolan, P. M., Liu, G., Yamamoto, M., Huso, D. L., & Kensler, T. W. (2007) · International Journal of Cancer · doi:10.1002/ijc.22943 · Cited by 197
PALB2 Interacts with KEAP1 To Promote NRF2 Nuclear Accumulation and Function
Ma, J., Cai, H., Wu, T., Sobhian, B., Huo, Y., Alcivar, A., Mehta, M., Cheung, K. L., Ganesan, S., Kong, A.-N. T., et al. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06271-11 · Cited by 192
Self-citationMethylation of the KEAP1 gene promoter region in human colorectal cancer
Hanada, N., Takahata, T., Zhou, Q., Ye, X., Sun, R., Itoh, J., Ishiguro, A., Kijima, H., Mimura, J., Itoh, K., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-66 · Cited by 190
Garg, R., Gupta, S., & Maru, G. B. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn064 · Cited by 185
The Keap1–Nrf2 Cell Defense Pathway – A Promising Therapeutic Target?
Copple, I. M. (2012) · Advances in Pharmacology · doi:10.1016/b978-0-12-398339-8.00002-1 · Cited by 171
Roebuck, B. D., Liu, Y. L., Rogers, A. E., Groopman, J. D., & Kensler, T. W. (1991) · PubMed · Cited by 162
Ooi, A., Dykema, K., Ansari, A., Petillo, D., Snider, J., Kahnoski, R., Anema, J., Craig, D., Carpten, J., Teh, B.-T., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3227 · Cited by 159 · cited 2×
“Gain-of-function mutations in NRF2 and loss-of-function mutations in KEAP1 and CUL3 have been identified in several human cancers (Padmanabhan et al. 2006; Singh et al. 2006; Nioi and Nguyen 2007; Ohta et al. 2008; Shibata et al. 2008a; Li et al. 2011; Ooi et al. 2013; Sato et al. 2013).”
BackgroundZhu, M., & Fahl, W. E. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5944 · Cited by 148
Identification of polymorphisms in the promoter region of the human NRF2 gene
Yamamoto, T., Yoh, K., Kobayashi, A., Ishii, Y., Kure, S., Kôyama, A., Sakamoto, T., Sekizawa, K., Motohashi, H., & Yamamoto, M. P. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.06.112 · Cited by 140
Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer
Muscarella, L. A., Parrella, P., D’Alessandro, V., la Torre, A., Barbano, R., Fontana, A., Tancredi, A., Guarnieri, V., Balsamo, T., Coco, M., et al. (2011) · Epigenetics · doi:10.4161/epi.6.6.15773 · Cited by 139
Shim, G.-S., Manandhar, S., Shin, D., Kim, T., & Kwak, M. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.09.006 · Cited by 131
Camp, N. D., James, R. G., Dawson, D. W., Yan, F., Davison, J. M., Houck, S. A., Tang, X., Zheng, N., Major, M. B., & Moon, R. T. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.316471 · Cited by 131
Chemoprotection by Organosulfur Inducers of Phase 2 Enzymes: Dithiolethiones and Dithiins
Kensler, T. W., Curphey, T. J., Maxiutenko, Y., & Roebuck, B. D. (2000) · Drug metabolism and drug interactions · doi:10.1515/dmdi.2000.17.1-4.3 · Cited by 131
Kensler, T. W., He, X., Otieno, M. A., Egner, P. A., Jacobson, L. P., Chen, B., Wang, J., Zhu, Y., Zhang, B.-C., Wang, J. B., et al. (1998) · PubMed · Cited by 129
Regulatory Nexus of Synthesis and Degradation Deciphers Cellular Nrf2 Expression Levels
Suzuki, T., Shibata, T., Takaya, K., Shiraishi, K., Kohno, T., Kunitoh, H., Tsuta, K., Furuta, K., Goto, K., Hosoda, F., et al. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00065-13 · Cited by 128
USP15 Negatively Regulates Nrf2 through Deubiquitination of Keap1
Villeneuve, N. F., Tian, W., Wu, T., Sun, Z., Lau, A., Chapman, E., Fang, D., & Zhang, D. D. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.04.022 · Cited by 126
Self-citationMorito, N., Yoh, K., Itoh, K., Hirayama, A., Kôyama, A., Yamamoto, M. P., & Takahashi, S. (2003) · Oncogene · doi:10.1038/sj.onc.1207024 · Cited by 115
Reddy, N. M., Kleeberger, S. R., Yamamoto, M. P., Kensler, T. W., Scollick, C., Biswal, S. S., & Reddy, S. P. (2007) · Physiological Genomics · doi:10.1152/physiolgenomics.00126.2007 · Cited by 114
Kuroiwa, Y., Nishikawa, A., Kitamura, Y., et al. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.10.028 · Cited by 101
p53 is activated in response to disruption of the pre-mRNA splicing machinery
Allende-Vega, N., Dayal, S., Agarwala, U., Sparks, A., Bourdon, J., & Saville, M. K. (2012) · Oncogene · doi:10.1038/onc.2012.38 · Cited by 98
Deficiency in Nrf2-GSH Signaling Impairs Type II Cell Growth and Enhances Sensitivity to Oxidants
Reddy, N. M., Kleeberger, S. R., Cho, H., Yamamoto, M. P., Kensler, T. W., Biswal, S. S., & Reddy, S. P. (2007) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2007-0004rc · Cited by 98
KEAP1 gene mutations and NRF2 activation are common in pulmonary papillary adenocarcinoma
Li, Q. K., Singh, A., Biswal, S., Askin, F., & Gabrielson, E. (2011) · Journal of Human Genetics · doi:10.1038/jhg.2010.172 · Cited by 90
Bardoxolone Brings Nrf2-Based Therapies to Light
Zhang, D. D. (2012) · Antioxidants and Redox Signaling · doi:10.1089/ars.2012.5118 · Cited by 81
Self-citationEPR imaging of reducing activity in Nrf2 transcriptional factor-deficient mice
Hirayama, A., Yoh, K., Nagase, S., Ueda, A., Itoh, K., Morito, N., Hirayama, K., Takahashi, S., Yamamoto, M. P., & Kôyama, A. (2003) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(03)00073-x · Cited by 81
Rao, C. V., Rivenson, A., Katiwalla, M., Kelloff, G. J., & Reddy, B. S. (1993) · PubMed · Cited by 81
Plafker, K. S., Nguyen, L., Barneche, M., Mirza, S., Crawford, D., & Plafker, S. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.121913 · Cited by 73
Fox, R. J., & Phillips, J. (2013) · Seminars in Neurology · doi:10.1055/s-0033-1343796 · Cited by 62
Konstantinopoulos, P. A., Fountzilas, E., Pillay, K., Zerbini, L. F., Libermann, T. A., Cannistra, S. A., & Spentzos, D. (2008) · BMC Medical Genomics · doi:10.1186/1755-8794-1-59 · Cited by 61
Wong, T. F., Yoshinaga, K., Monma, Y., Ito, K., Niikura, H., Nagase, S., Yamamoto, M. P., & Yaegashi, N. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31822d0eb2 · Cited by 43
Thimmulappa, R. K., Rangasamy, T., Alam, J., & Biswal, S. S. (2008) · Medicinal Chemistry · doi:10.2174/157340608785700199 · Cited by 39
The Extinguished BEACON of Bardoxolone: Not a Monday Morning Quarterback Story
Tayek, J. A., & Kalantar‐Zadeh, K. (2013) · American Journal of Nephrology · doi:10.1159/000346950 · Cited by 36
Safety and Efficacy of Weekly Oral Oltipraz in Chronic Smokers
Kelley, M. J., Glaser, E. M., Herndon, J. E., Becker, F. O., Bhagat, R., Zhang, Y., Santella, R. M., Carmella, S. G., Hecht, S. S., Gallot, L., et al. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0585 · Cited by 36
Clapper, M. L., Wood, M., Leahy, K. J., et al. (1995) · Carcinogenesis · doi:10.1093/carcin/16.9.2159 · Cited by 31
Sharma, S. (2005) · Carcinogenesis · doi:10.1093/carcin/bgl052 · Cited by 26
Mechanisms of Drug Action: The Potential of Dimethylfumarate for the Treatment of Neoplasms
Chen, A. F., & Kirsner, R. S. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.105 · Cited by 14
Research works printed but not linked: 8
- 2004, Breast cancer risk in premenopausal women is inversely associated with consumption of broccoli, a source of isothiocyanates, but is not modified by GST genotype, J Nutr, 134, 1134, 10.1093/jn/134.5.1134 · doi:10.1093/jn/134.5.1134
- 10.1207/s15327914nc5002_11 · doi:10.1207/s15327914nc5002_11
- 1998, Use of aflatoxin adducts as intermediate endpoints to assess the efficacy of chemopreventive interventions in animals and man, Mutat Res, 402, 165, 10.1016/S0027-5107(97)00294-7 · doi:10.1016/s0027-5107(97)00294-7
- 10.1093/carcin/14.11.2423 · doi:10.1093/carcin/14.11.2423
- 1994, Chemoprevention of respiratory-tract neoplasia in the hamster by oltipraz, alone and in combination, Int J Oncol, 4, 661
- 1996, Inhibition of 2-amino-1-methyl-6-phenylimidazo[4,5]pyridine-induced lymphoma formation by oltipraz, Cancer Res, 56, 3395
- 2012, Genotype analysis of the NRF2 gene mutation in lung cancer, Int J Mol Med, 31, 1135
- 2000, Dietary intake of isothiocyanates: Evidence of a joint effect with glutathione S-transferase polymorphisms in lung cancer risk, Cancer Epidemiol Biomarkers Prev, 9, 1017
Cited by
ROS function in redox signaling and oxidative stress
Schieber, M., & Chandel, N. S. (2014) · Current Biology · doi:10.1016/j.cub.2014.03.034 · Cited by 6,931
Fundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013
Dixon, S. J., Patel, D. N., Welsch, M., Skouta, R., Lee, E. D., Hayano, M., Thomas, A. G., Gleason, C. E., Tatonetti, N. P., Slusher, B. S., et al. (2014) · eLife · doi:10.7554/elife.02523 · Cited by 2,088
Nrf2-Keap1 signaling in oxidative and reductive stress
Bellezza, I., Giambanco, I., Minelli, A., & Donato, R. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.02.010 · Cited by 2,053
Sun, X., Ou, Z., Chen, R., Niu, X., Chen, D., Kang, R., & Tang, D. (2016) · Hepatology · doi:10.1002/hep.28251 · Cited by 2,012
Metadata
- Authors
- Jaramillo, M. C., & Zhang, D. D.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2013-10-15
- Volume
- 27
- Issue
- 20
- Pages
- 2179-2191
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2138271341
- Cited by
- 1,297
- References
- 137
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.